Abstracts

Results Multiplex immunohistochemistry detected SARS-CoV-2 nucleocapsid protein only in adjacent normal liver tissue but not within tumour core (figure 2). We also observed SARS-CoV-2 in some immune cells such as sinusoidal Kupffer cells (figure 2). Additionally, upon stimulation with SARS-CoV-2 peptides, we successfully elicited SARS-CoV-2-specific memory response which is distinct from the response upon challenge with HBV peptides. These findings were similar to our previous discovery in a patient with colorectal adenocarcinoma where we have shown viral antigen detection, validated with PCR to detect viral RNA, as well as the detection of SARS-CoV-2 memory-like T cells in situ (figure 2). Deep profiling of the samples is on-going with single-cell analysis and digital spatial profiling.

Conclusions We believe this is the first immune profiling report of the in situ tumour microenvironment in a cancer patient with COVID-19. Our findings demonstrated the presence of viral proteins in the liver despite negative swab test result and the ability to elicit ex vivo SARS-CoV-2-specific immune responses through peptide stimulation assays. We also detected same immune cell phenotypes in situ in the cancer

tissues. Taken together, we propose caution when handling tissues from patients who have a recent history of COVID-19, particularly during aerosol-generating procedures such as ultrasonic dissection surgery.

Ethics Approval This study was approved by Centralised Institutional Review Board of SingHealth, approval number 2019/2653.

Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

REFERENCES

1. Yao XH, He ZC, Li TY, Zhang HR, Wang Y, Mou H, *et al*. Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient. *Cell Res* 2020;**30**(6):541-3.
2. Qian Q, Fan L, Liu W, Li J, Yue J, Wang M, *et al*. Direct evidence of active SARS-CoV-2 replication in the intestine. *Clin Infect Dis* 2020.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0825>

826

RISK OF COVID-19 INFECTION AMONG PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITOR THERAPY: A TERTIARY CARE HOSPITAL SYSTEM COLLABORATION WITH THE MASSACHUSETTS DEPARTMENT OF HEALTH

¹William Murphy, ¹Vartan Pahalyants*, ²Nikolai Klebanov, ²Nicholas Theodosakis, ²Leyre Zubiri, ³Monina Kleven, ²Evelyn Lilly, ²Kerry Reynolds, ²Yevgeniy Semenov. ¹Harvard Medical School, Chestnut Hill, MA, USA; ²Massachusetts General Hospital, Boston, MA, USA; ³Mass Department of Public Health, Boston, MA, USA

Background It is unclear whether treatment with immune checkpoint inhibitors (ICIs) is a risk factor for contracting COVID-19. We investigated whether patients prescribed ICIs were more or less likely to contract COVID-19 than matched controls in a collaboration between a large academic health-care system and the Massachusetts Department of Health.

Methods We performed a retrospective study of 1,577 cancer patients prescribed ICI and 26,241 matched controls. We included all patients infused with an ICI in the Mass General Brigham (MGB) network between 7/1/19 and 2/29/20 and

Abstract 825 Figure 2 Immunohistochemical staining of the SARS-CoV-2 nucleocapsid protein and immune profiling with 25-colour flow cytometry in normal colon and liver tissue a, Liver tissues were immunostained with SARS-CoV-2 nucleocapsid protein (NP), nuclei were counterstained with haematoxylin. Positive SARS-CoV-2 nucleocapsid staining in benign hepatocytes and sinusoidal Kupffer cells. Scale bar represents 50µm. b, Multiplex immunohistochemistry of normal liver tissue. From left to right, top to bottom: SARS-CoV-2 nucleocapsid (green), SARS-CoV-2 nucleocapsid (green) with CD14 (red), SARS-CoV-2 nucleocapsid (green) with CD68 (pink) and composite. Co-localisation were observed as shown by the white arrows. Scale bar represents 100µm. c, Colon tissues were immunostained with SARS-CoV-2 nucleocapsid protein, nuclei were counterstained with haematoxylin. Positive SARS-CoV-2 nucleocapsid staining in colonic crypts, with granular supranuclear cytoplasmic pattern. Scale bar represents 50µm. d, Multiplex immunohistochemistry of colon tissue. From left to right, top to bottom: DAPI (blue), CD3 (magenta), CD38 (green), granzyme B (yellow), interferon-gamma (red) and composite. Co-localisation was observed as shown by the white arrows. Scale bar represents 100µm, Magnification x200. e, Flow cytometry immune profiling of blood from colorectal cancer patient with COVID-19 following stimulation with SARS-CoV-2 peptides. Highlighted populations showed CD3 cells expressing CD38, supporting the CD3+ CD38+ co-localization findings observed in (c).

Abstract 826 Table 1 Multivariable logistic regression for patients treated with ICI with Odds Ratios for defining 'event' to be COVID-19 positivity

	OR	95% CI	p-value
ICI use	0.7	0.45 – 1.09	0.11
Age			
18–44	ref*	ref*	ref*
45–64	0.86	0.56 – 1.32	0.49
65–74	0.54	0.34 – 0.86	0.01
74+	0.97	0.61 – 1.56	0.91
Sex Female	1.08	0.91 – 1.28	0.39
Race and Ethnicity			
Non-Hispanic White	ref*	ref*	ref*
Non-Hispanic Asian or Pacific Islander	2.38	1.60 – 3.54	<0.001
Non-Hispanic Black	1.63	1.10 – 2.42	0.02
Non-Hispanic Other	1.77	1.08 – 2.93	0.03
Hispanic	0	0.00 – Inf	0.99
Unknown	1.76	1.06 – 2.92	0.03
CCI grade			
Mild (1-2)	ref*	ref*	ref*
Moderate (3-4)	3.01	1.45 – 6.28	0.00
Severe (≥5)	3.97	1.88 – 8.38	<0.001
Comorbidity			
Median income in \$1,000s	0.90	0.87 – 0.94	<0.001
COVID-19 town or county positivity rate per 100,000	1.22	1.15 – 1.30	<0.001

generated an exact match of control patients from the MGB database on age, sex, and Charlson comorbidity index. For both groups, we cross referenced COVID-19 infection data through June 19, 2020 from the Massachusetts Department of Public Health using date of birth, last name, and first four letters of the first name. We calculated odds ratios (OR) for COVID-19 diagnosis using a multivariate logistic regression adjusting for age, sex, race, CCI, zip code income, and local infection rate.

Results Twenty-one patients (1.3%) prescribed ICIs and 527 controls (2.0%) were identified as COVID positive in the Massachusetts department of health database. When controlling for local infection rate, age, sex, race, CCI, and zip code income, there were no significant differences in COVID infection between ICI recipients and matched controls (OR: 0.7, 95% CI: 0.45 – 1.09, $p=0.1$; table 1).

Conclusions In our experience, patients who were prescribed ICI were not more likely to contract COVID-19 than matched controls, which may assist in decision-making around continuation of therapy during the pandemic. More research needs to be conducted to determine potential behavioral and testing factors that may affect COVID-19 diagnosis.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0826>

Immune cell biology

827 ELUCIDATING THE ROLES OF PIK3IP1/TRIP IMMUNE REGULATION ON DISTINCT T CELL SUBSETS IN THE CONTEXT OF CANCER

Benjamin Murter*, Lawrence Kane. *University of Pittsburgh, Pittsburgh, PA, USA*

Background The signaling pathways involving phosphoinositide-3-kinases (PI3Ks) are highly conserved and tightly regulated to influence the activation, proliferation, and survival of all cell types. PI3K signaling plays a major role in T cell responses to antigen due to its position directly downstream of T cell receptor (TCR)/CD28 ligation. Our lab has recently shown that the cell surface protein TrIP (Transmembrane Inhibitor of PI3K, gene name: Pik3ip1) is capable of downregulating PI3K signaling in CD4+ T cells and can act as a negative regulator of T cell immune responses.¹ This negative immune regulation was just recently reported to promote anti-tumor immunity, implicating TrIP as a potential immunotherapy target.² Interestingly, although all effector subsets express TrIP to varying degrees, public expression data shows that Treg cells maintain higher TrIP message than other T-effector subsets.³

Methods Using a conditional TrIP knockout mouse model developed in our lab, we have begun to interrogate how TrIP expression regulates the opposing activities of CD8+ T cells vs. Treg and how these affect the overall tumor immune landscape. With Treg-specific TrIP KO, we assessed the effects on syngeneic tumor growth in vivo, as well as analyzed primary and tumor-derived Treg phenotypes ex-vivo.

Results Thus far, we have found that TrIP knockout in the Treg compartment leads to no detectable differences in tumor burden. However, the lack of TrIP expression on Treg does have some effect on the effector phenotype of Treg cells isolated from the tumor.

Conclusions We describe preliminary data on the role of TrIP in Treg function and phenotype and have begun to explore its

effects on the tumor microenvironment. To build on this work we are currently developing TrIP over-expressing lentiviral constructs to compliment the knockout approaches described here. We have also now obtained mice with tamoxifen-inducible TrIP KO in Treg, so we will determine whether the timing of TrIP deletion affects the impact of TrIP deficiency.

REFERENCES

1. Uche UU, Piccirillo AR, Kataoka S, Grebinski SJ, D'Cruz LM, Kane LP. PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt. *J Exp Med* 2018;**215**:3165–3179. doi:10.1084/jem.20172018.
2. Chen Y, Wang J, Wang X, Li X, Song J, Fang J, et al. Pik3ip1 Is a Negative Immune Regulator that Inhibits Antitumor T-Cell Immunity. *Clin Cancer Res* 2019;**25**:6180–6194. doi:10.1158/1078-0432.CCR-18-4134.
3. Heng TSP, Painter MW, Immunological Genome Project Consortium. The immunological genome project: networks of gene expression in immune cells. *Nat Immunol* 2008;**9**:1091–1094. doi:10.1038/ni1008-1091.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0827>

828 IMPROVED GROWTH PROPERTIES AND IMMUNE SURVEILLANCE IN K-RAS G12V-TRANSFORMED CELLS THROUGH OVEREXPRESSION OF BIGLYCAN

Karthikeyan Subbarayan*, Sandra Leisz, Chiara Massa, Sravankumar Balina, Anja Müller, Claudia Wickenhauser, Barbara Seliger. *Martin-Luther-University Halle-Wittenberg, Halle, Germany*

Background The extracellular matrix protein biglycan (BGN) plays an essential role in matrix assembly, cellular migration, adhesion, proliferation and apoptosis. Recently, BGN expression has been shown to be impaired upon HER-2/neu overexpression, which was associated with an up-regulation of MHC class I surface expression. However, there exists no information about the link between K-RAS-mediated immune escape and BGN expression.

Methods In vitro models of human K-RAS G12V transformed mouse fibroblasts and two human colorectal carcinoma (CRC) cell lines carrying a K-RAS G12V mutation (RKO and SW480) were used for the analysis of BGN expression by qPCR and Western blot. At the same time, the major histocompatibility complex (MHC) class I surface expression, as well as CD4+ and CD8+ cells, were determined by flow cytometry. The different K-RAS G12V cells and respective controls were stably transfected with BGN. Growth properties were analyzed by proliferation, migration and invasion assays. Luciferase reporter assays were used to determine the transcriptional regulation of MHC class I APM components. Tumorigenicity of BGN transfectants in comparison to control cells was evaluated by injection of respective transfectants s.c. into mice and tumor growth was monitored over time.

Results Both murine and human K-RAS G12V cells express low levels of BGN compared to control cells. Overexpression of BGN caused an inhibition of cell proliferation, a diminished anchorage-independent growth and a reduced migration rate. The altered in vitro growth properties of BGNhigh K-RAS G12V+ correlated with a delayed tumor growth and a reduced frequency of tumor formation in vivo. Restoration of BGN expression increased the expression of decorin as well as enhanced MHC class I expression in K-RAS G12V-transformed cells. This is due to a BGN-induced transcriptional upregulation of major components of the MHC class I antigen processing machinery (APM), such as the transporter associated with antigen processing TAP1, TAP2 and LMP2, in BGN transfectants of K-RAS G12V+ cells. The results were further